drugset / Trial / NCT01402492
Cocaine Use Reduction With Buprenorphine
Phase 2/3
Completed
302 enrolled
University of California, Los Angeles
National Institute on Drug Abuse (NIDA) · collabThe Emmes Company, LLC · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of this study is to investigate the safety and effectiveness of buprenorphine in the presence of naltrexone for the treatment of cocaine dependence.
Timeline
- Start
- 2011-09
- Primary completion
- 2013-01
- Completion
- 2013-03
Outcome
Missed primary endpoint
paper No group differences were found between groups for the primary outcome (BUP4 versus PLB, P = 0.262; BUP16 versus PLB, P = 0.185). PMID 26948856 ↗
Publications
- Results Ling W, Hillhouse MP, Saxon AJ, Mooney LJ, Thomas CM, Ang A, Matthews AG, Hasson A, Annon J, Sparenborg S, Liu DS, McCormack J, Church S, Swafford W, Drexler K, Schuman C, Ross S, Wiest K, Korthuis PT, Lawson W, Brigham GS, Knox PC, Dawes M, Rotrosen J. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction. 2016 Aug;111(8):1416-27. doi: 10.1111/add.13375. Epub 2016 Apr 21.
- Mooney LJ, Nielsen S, Saxon A, Hillhouse M, Thomas C, Hasson A, Stablein D, McCormack J, Lindblad R, Ling W. Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology. Contemp Clin Trials. 2013 Mar;34(2):196-204. doi: 10.1016/j.cct.2012.11.002. Epub 2012 Nov 16.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buprenorphine | Other / unclassified | 4 mg | Other |
| Subject | Buprenorphine | Other / unclassified | 16 mg | Other |
| Background | Naltrexone | Small molecule | — | Other |